Cellular immunotherapy for refractory hematological malignancies

BACKGROUND: Acute myeloid leukemia (AML) and other aggressive refractory hematological malignancies unresponsive to upfront therapy remain difficult conditions to treat. Often, the focus of therapy is centered on achieving complete remission of disease in order to proceed with a consolidative stem c...

詳細記述

保存先:
書誌詳細
主要な著者: Reagan, John L, Fast, Loren D, Safran, Howard, Nevola, Martha, Winer, Eric S, Castillo, Jorge J, Butera, James N, Quesenberry, Matthew I, Young, Carolyn T, Quesenberry, Peter J
フォーマット: Artigo
言語:Inglês
出版事項: BioMed Central 2013
主題:
Protocol
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3689050/
https://ncbi.nlm.nih.gov/pubmed/23782682
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1479-5876-11-150
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料